Pharmacogenomics of Pain and Medication Response | Decoding Inflammation

By Alberto Rivera, MD · 2026-05-13 · 6 min read

The Metabolism Problem That Precedes the Pain Problem

Chronic pain medicine has long operated on a model of dose titration and trial-and-error medication selection. What pharmacogenomics reveals is that this trial-and-error process is not random, it is structured by the genome. The same opioid dose that provides adequate analgesia in one patient may be metabolized too rapidly to achieve therapeutic plasma levels in another, or too slowly, creating toxicity in a third.

CYP2D6, the enzyme responsible for metabolizing codeine, tramadol, oxycodone, and numerous antidepressants used in pain management, exhibits extreme pharmacogenomic variability. More than 100 functional alleles have been characterized, producing phenotypes ranging from poor metabolizer (no functional enzyme) to ultrarapid metabolizer (multiple gene copies with amplified activity).

The OPRM1 Receptor Layer

Beyond metabolism, opioid efficacy depends on the receptor itself. The OPRM1 gene encodes the mu-opioid receptor, and its A118G variant, rs1799971, reduces receptor expression by approximately 70 percent in the brain. G allele carriers require substantially higher opioid doses to achieve equivalent analgesia because they simply have fewer receptors available to transduce the signal.

A 2024 randomized controlled trial in Pain confirmed that A118G G/G homozygotes required 40 percent higher morphine equivalents for postoperative pain control than A/A carriers. Without genomic knowledge, clinicians observing this pattern may attribute the higher dosing requirement to drug-seeking behavior. With it, they can recognize a receptor-level pharmacogenomic reality.

NSAIDs and CYP2C9

Non-steroidal anti-inflammatory drugs, ibuprofen, diclofenac, celecoxib, are metabolized by CYP2C9. Poor metabolizer alleles *2 and *3 reduce enzyme activity by 30 to 95 percent, extending drug half-life and elevating both therapeutic effect and gastrointestinal and renal toxicity risk. In chronic pain patients requiring long-term NSAID use, CYP2C9 genotyping is not an academic consideration. It is a safety determination.

The GENEFLAMMATION protocol integrates pharmacogenomic profiling for pain management medications as a clinical service for patients with chronic inflammatory pain, translating genotype into dosing guidance, drug selection, and monitoring parameters calibrated to the specific metabolic architecture the genome reveals.